Study guide
3.2 Respiratory Disorders & Acute Emergencies
Clinical Officers Council Pre-Internship Examination Kenya
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Overview & Exam Strategy
1.1 About the COC Pre-Internship Examination 1.2 Clinical Decision-Making & Preparation Strategy
2 Chapter 2: Infectious & Communicable Diseases (Internal Medicine)
2.1 Malaria Diagnosis & Case Management 2.2 Tuberculosis & Leprosy Control 2.3 HIV/AIDS & Opportunistic Infections 2.4 Enteric & Neglected Tropical Infections
3 Chapter 3: Cardiovascular & Respiratory Medicine (Internal Medicine)
3.1 Hypertension & Cardiovascular Disorders 3.2 Respiratory Disorders & Acute Emergencies 3.3 Venous Thromboembolism & Vascular Emergencies
4 Chapter 4: Metabolic, Gastrointestinal & Neurological Medicine (Internal Medicine)
4.1 Diabetes Mellitus & Endocrine Emergencies 4.2 Gastrointestinal & Hepatorenal Disorders 4.3 Neurological Emergencies & Acute Toxicology
5 Chapter 5: Trauma Resuscitation & Emergency Surgery (General Surgery)
5.1 ATLS Primary Survey & Trauma Resuscitation 5.2 Burn Assessment & Fluid Resuscitation 5.3 Surgical Wounds, Infections & Tetanus Prophylaxis
6 Chapter 6: Acute Abdomen & Gastrointestinal Surgery (General Surgery)
6.1 Acute Appendicitis & Peritonitis 6.2 Intestinal Obstruction & Abdominal Hernias 6.3 Hepatobiliary, Pancreatic & Anorectal Surgical Conditions
7 Chapter 7: Orthopedics, Urology & Special Surgical Emergencies (General Surgery)
7.1 Fractures, Dislocations & Cast Management 7.2 Acute Compartment Syndrome & Limb Emergencies 7.3 Urological Emergencies & Pelvic Trauma 7.4 Emergency Airway, Anesthesia & Oncology Screening
8 Chapter 8: Essential Newborn Care & Neonatal Conditions (Pediatrics)
8.1 Immediate Newborn Care & Neonatal Resuscitation 8.2 Neonatal Jaundice, Sepsis & Common Disorders 8.3 Low Birth Weight & Kangaroo Mother Care
9 Chapter 9: IMCI Guidelines & Common Pediatric Conditions (Pediatrics)
9.1 IMCI Principles & General Danger Signs 9.2 Cough, Fast Breathing & Pediatric Pneumonia 9.3 Pediatric Diarrheal Diseases & Dehydration 9.4 Acute Pediatric Infections: Meningitis, Croup & Febrile Seizures
10 Chapter 10: Child Nutrition, KEPI & Preventive Pediatrics (Pediatrics)
10.1 Severe Acute Malnutrition (SAM) Management 10.2 KEPI Immunization Schedule & Vaccine Logistics 10.3 Pediatric Prophylaxis & Early Infant Diagnosis
11 Chapter 11: Antenatal Care & Medical Complications of Pregnancy (Obstetrics & Gynecology)
11.1 Focused Antenatal Care & Routine ANC Screening 11.2 Hypertensive Disorders of Pregnancy & Eclampsia 11.3 Medical Disorders & Infections in Pregnancy
12 Chapter 12: Labor, Delivery & Obstetric Emergencies (Obstetrics & Gynecology)
12.1 Normal Labor & Partograph Monitoring 12.2 Active Management of the Third Stage of Labor & PPH 12.3 Antepartum Hemorrhage & Uterine Rupture 12.4 Induction of Labor & Malpresentation Emergencies
13 Chapter 13: Puerperium, Gynecological Disorders & Family Planning (Obstetrics & Gynecology)
13.1 Puerperal Sepsis & Postnatal Complications 13.2 Pelvic Inflammatory Disease & Gynecological Conditions 13.3 Modern Contraceptive Technology & WHO MEC Criteria
14 Chapter 14: Primary Health Care & Devolved Health Systems (Community Health)
14.1 Primary Health Care Principles & Universal Health Coverage 14.2 Kenya Health Service Delivery Structure & Devolved Governance 14.3 Kenya Community Health Strategy & Level 1 Services
15 Chapter 15: Epidemiology, Disease Surveillance & Outbreak Response (Community Health)
15.1 Epidemiological Principles & Health Indicators 15.2 Integrated Disease Surveillance and Response (IDSR) 15.3 Vector Control & Neglected Tropical Diseases
16 Chapter 16: Environmental Health, Waste Management & Cold Chain (Community Health)
16.1 Water Quality & Household Water Treatment 16.2 Community Sanitation & Excreta Disposal 16.3 Healthcare Waste Management & Infection Prevention Control 16.4 Vaccine Cold Chain Management & Quality Monitoring
17 Chapter 17: Health Systems Management — Leadership, Policy & Financing
17.1 Management Functions, Leadership & Supportive Supervision 17.2 Kenya Health Policy, Planning & the Devolved Budget Cycle 17.3 Health Financing & Universal Health Coverage under the Social Health Authority 17.4 Human Resource Management, Scheme of Service & Performance Appraisal
18 Chapter 18: Health Commodities, Information & Quality Management
18.1 Health Commodity & Supply Chain Management (KEMSA) 18.2 Health Information Systems, Records & KHIS Reporting 18.3 Quality Improvement, Clinical Audit & Patient Safety
19 Chapter 19: Professional Practice, Ethics & Medico-Legal Responsibility
19.1 Scope of Practice, Registration, Licensing & Professional Discipline 19.2 Medical Ethics, Informed Consent & Patient Rights 19.3 Medico-Legal Documentation, Statutory Notification & Facility Safety Governance
3.2 Respiratory Disorders & Acute Emergencies
Key Takeaways Explain This Topic AI
Community-Acquired Pneumonia (CAP) severity is objectively triaged using the CURB-65 score (Confusion, Urea > 7 mmol/L, Respiratory rate >= 30/min, Blood pressure < 90/60 mmHg, Age >= 65 years); scores 0–1 qualify for outpatient oral therapy, score 2 warrants admission, and scores >= 3 mandate urgent inpatient or ICU admission.
Aspiration pneumonia involves anaerobic oral flora and dependent lung segment infiltration; initial therapeutic coverage must include anaerobic coverage such as Amoxicillin-clavulanate or Ceftriaxone combined with Metronidazole.
Life-threatening asthma exacerbation is characterized by a silent chest, central cyanosis, exhaustion, peak expiratory flow < 33%, and critically, a 'normal' or rising PaCO2 indicating impending respiratory muscle fatigue and impending fatal respiratory arrest.
Immediate management of severe acute asthma requires high-flow oxygen, frequent or continuous nebulized Salbutamol combined with Ipratropium bromide, early systemic corticosteroids (oral Prednisolone or IV Hydrocortisone), and intravenous Magnesium Sulphate for refractory bronchospasm.
Acute exacerbation of COPD (AECOPD) requires controlled low-flow oxygen targeting SpO2 88–92% to prevent hyperoxia-induced loss of hypoxic drive, worsening V/Q mismatch, and hypercapnic coma; antibiotics are indicated when sputum purulence is present (Anthonisen criteria).
Last updated: September 2026
3.2 Respiratory Disorders & Acute Emergencies
Core Clinical Rule: In severe acute asthma, a normal or elevated PaCO 2 \text{PaCO}_2 PaCO 2 ( > 40 mmHg / 5.3 kPa > 40\text{ mmHg} / 5.3\text{ kPa} > 40 mmHg /5.3 kPa ) in an exhausted patient with a silent chest is a medical catastrophe heralding impending respiratory arrest . In acute COPD exacerbations, never administer uncontrolled high-flow oxygen; titrate strictly to an S p O 2 SpO_2 Sp O 2 of 88% to 92% to avoid abolishing hypoxic pulmonary vasoconstriction and inducing fatal hypercapnic narcosis.
Respiratory emergencies account for a substantial volume of acute hospital admissions across Kenyan county referral hospitals. Clinical officers must rapidly distinguish benign presentations from decompensating respiratory failure using validated risk stratification instruments and initiate prompt, evidence-based antimicrobial and bronchodilator protocols.
1. Community-Acquired Pneumonia (CAP)
Community-Acquired Pneumonia is defined as an acute infection of the pulmonary parenchyma acquired outside of a healthcare facility or developing within 48 hours of hospital admission.
Microbial Etiology
Typical Bacterial Pathogens:
Streptococcus pneumoniae (Pneumococcus): The single most common causative organism globally and across all age groups in Kenya. Characterized by sudden onset high rigors, productive cough with rust-colored sputum , and dense lobar consolidation on chest radiography.
Haemophilus influenzae: Common in patients with underlying COPD, bronchiectasis, and elderly smokers.
Staphylococcus aureus: Classically causes severe necrotizing pneumonia following an antecedent viral influenza infection; prone to cavitation, pneumatoceles, and spontaneous pneumothorax.
Klebsiella pneumoniae: Common in patients with severe alcohol use disorder, diabetes, or malnutrition. Characterized by thick, gelatinous 'currant jelly' sputum , upper lobe predilection, bulging fissures, and early lung abscess formation.
Atypical Pathogens:
Mycoplasma pneumoniae: Frequent in adolescents and young adults residing in communal settings (schools, barracks). Manifests with non-productive hacking cough, headache, low-grade fever, prominent extrapulmonary features (bullous myringitis, autoimmune hemolytic anemia due to cold agglutinins, erythema multiforme), and diffuse interstitial reticular infiltrates.
Chlamydophila pneumoniae: Mild, indolent respiratory presentation with prominent pharyngitis and hoarseness.
Legionella pneumophila: Transmitted via aerosolized water sources (air conditioning cooling towers, hospital showers). Characterized by severe pneumonia accompanied by high fever, confusion/encephalopathy, gastrointestinal symptoms (watery diarrhea), hyponatremia (due to SIADH), and transaminitis.
Clinical Presentation and Physical Examination
Classic physical signs of pulmonary lobar consolidation include:
Dullness to percussion over the involved lung segment.
Increased tactile vocal fremitus and vocal resonance.
Bronchial breath sounds (harsh, hollow, with prolonged expiration and a pause between inspiration and expiration).
Inspiratory crackles (rales) that do not clear with coughing.
Egophony (spoken 'E' heard as nasal 'A' through the stethoscope) and whispered pectoriloquy.
CURB-65 Severity Stratification and Triage
The CURB-65 score is an objective prognostic instrument validated to determine the appropriate site of clinical care and calculate 30-day mortality risk: +-----------------------------------------------------------------------------------+
- | THE CURB-65 SCORING RUBRIC |
- +-----------------------------------------------------------------------------------+
- | C - Confusion: Abbreviated Mental Test Score (AMTS) <= 8 or new disorientation | [1 pt]
- | U - Urea: Blood Urea Nitrogen > 7.0 mmol/L (> 19 mg/dL) | [1 pt]
- | R - Respiratory Rate: >= 30 breaths per minute | [1 pt]
- | B - Blood Pressure: Systolic < 90 mmHg OR Diastolic <= 60 mmHg | [1 pt]
- | 65 - Age: >= 65 years | [1 pt]
- +-----------------------------------------------------------------------------------+
Score Risk Category 30-Day Mortality Recommended Site of Care & Antimicrobial Regimen
0–1 Low Risk 1.5–2.5% Outpatient: Oral Amoxicillin 500 mg–1 g PO 8-hourly for 5 days. (Alternative: Oral Doxycycline 100 mg 12-hourly or Azithromycin 500 mg day 1, then 250 mg daily)
2 Moderate Risk 8.5–9.2% Inpatient (General Medical Ward): Oral Amoxicillin-clavulanate 625 mg PO 8-hourly OR IV Ampicillin 1–2 g 6-hourly / IV Ceftriaxone 1–2 g daily + Oral Azithromycin 500 mg daily
3–5 High / Severe Risk 15–40% Urgent Inpatient / HDU or ICU: IV Ceftriaxone 2 g daily (or IV Ampicillin-sulbactam 3 g 6-hourly) PLUS IV Azithromycin 500 mg daily (or IV Levofloxacin 750 mg daily). ICU mandatory if mechanical ventilation or septic shock requiring vasopressors
Aspiration Pneumonia
Aspiration pneumonia occurs when colonized oropharyngeal or gastric secretions enter the lower respiratory tract, typically in patients with impaired consciousness (intoxication, seizures, stroke, general anesthesia) or severe dysphagia.
Anatomical Distribution: When supine, secretions preferentially pool in the superior segment of the right lower lobe or the posterior segment of the right upper lobe due to the wider, more vertical course of the right main bronchus.
Microbiology: Polymicrobial infection combining oral anaerobes ( Peptostreptococcus , Fusobacterium nucleatum , Prevotella , Bacteroides ) and aerobes.
Therapeutic Regimens: Amoxicillin-clavulanate 1.2 g IV 8-hourly, OR Ampicillin-sulbactam 1.5–3 g IV 6-hourly, OR IV Ceftriaxone 2 g daily combined with IV Metronidazole 500 mg 8-hourly. (Clindamycin 600 mg IV 8-hourly is an alternative in penicillin-allergic patients).
2. Acute Asthma Exacerbation
Asthma is a chronic inflammatory disorder of the airways characterized by bronchial hyperresponsiveness, reversible airflow obstruction, mucosal edema, and smooth muscle bronchospasm.
Severity Grading of Acute Exacerbations
- Assessment Parameter Mild to Moderate Severe Life-Threatening (Near-Fatal)
- Speech Talks in sentences / phrases Talks in single words Unable to speak; exhausted
- Posture Prefers sitting to lying Sits upright, hunched forward (tripod) Collapsed, unable to maintain posture
- Mental State Calm or mildly anxious Agitated, distressed Confused, drowsy, comatose
- Respiratory Rate Increased (20–25/min) > 30 > 30 > 30 breaths/min Tachypneic or agonal / bradypneic
Accessory Muscles Minimal or none Marked sternocleidomastoid indrawing Exhaustion; paradoxical abdominal breathing
- Wheezing Moderate, expiratoy Loud, biphasic Silent chest (no wheeze audible)
- Heart Rate 100–120 bpm > 120 > 120 > 120 bpm Bradycardia, hypotension, arrhythmia
Peak Flow (PEF) 50–75% of personal best < 50 % < 50\% < 50% of personal best < 33 % < 33\% < 33% of personal best (or untestable)
Pulse Oximetry ( S p O 2 SpO_2 Sp O 2 ) 92–95% on room air < 90 % < 90\% < 90% on room air Cyanotic; severe refractory hypoxemia
PaCO 2 \text{PaCO}_2 PaCO 2 (on ABG) Low ( < 35 mmHg < 35\text{ mmHg} < 35 mmHg ; alkalosis) Normalizing (35–40 mmHg) Elevated ( > 42 mmHg > 42\text{ mmHg} > 42 mmHg ; hypercapnic arrest)
Caution
The Deadly 'Normal' Blood Gas in Asthma: An asthmatic patient who is hyperventilating should naturally blow off carbon dioxide, producing hypocapnia and respiratory alkalosis. A 'normal' PaCO 2 \text{PaCO}_2 PaCO 2 of 40 mmHg in a breathless, fatigued patient indicates that respiratory muscle exhaustion has set in. Without immediate intervention, severe hypercapnic respiratory arrest will follow rapidly.
Stepwise Emergency Pharmacological Protocol
Oxygen Therapy: Deliver humidified high-flow oxygen via a face mask or Venturi device to maintain an S p O 2 SpO_2 Sp O 2 target of 93% to 95% in adults (94% to 98% in children).
Inhaled Short-Acting Beta-2 Agonist (SABA):
Salbutamol (Albuterol): 2.5–5 mg nebulized with oxygen (driven at 6–8 L/min) every 20 minutes for 3 doses, or 4 to 10 puffs via a Metered Dose Inhaler (MDI) with a large-volume spacer. In severe or life-threatening distress, administer continuous nebulization at 10–15 mg/hour.
Inhaled Short-Acting Muscarinic Antagonist (SAMA):
Ipratropium Bromide: 500 mcg nebulized together with salbutamol every 20 minutes for the first hour (3 doses). Ipratropium blocks muscarinic M 3 M_3 M 3 receptors, reversing cholinergic bronchoconstriction and decreasing mucus hypersecretion.
Systemic Corticosteroids (Immediate Administration):
Prednisolone: 40–50 mg PO daily for 5 to 7 days, OR
Hydrocortisone: 100–200 mg IV every 6 hours if the patient is vomiting, unable to swallow, or in extremis. Systemic steroids suppress airway inflammation, up-regulate beta-2 receptors, and reduce relapse rates. Tapering is unnecessary for courses lasting <= 10 days.
Intravenous Magnesium Sulphate:
Administer Magnesium Sulphate 1.2–2 g IV (in 100 mL 5 % 5\% 5% dextrose or normal saline) infused over 20 minutes for patients with severe exacerbations unresponsive to initial nebulization, or life-threatening asthma. Magnesium acts as a physiological calcium antagonist, inducing bronchial smooth muscle relaxation.
Mechanical Ventilation: Indications include respiratory arrest, deterioration in conscious level, persistent exhaustion, and worsening hypercapnic acidosis ( p H < 7.25 pH < 7.25 p H < 7.25 ). Rapid Sequence Intubation (RSI) should utilize Ketamine (1–2 mg/kg IV) as the induction agent due to its sympathetic bronchodilatory properties.
Chronic Asthma Management (Global Initiative for Asthma - GINA Guidelines)
GINA Track 1 (Preferred Strategy): Reliever and controller therapy are integrated. The preferred reliever is as-needed low-dose Inhaled Corticosteroid (ICS) combined with Formoterol (e.g., Budesonide-formoterol 160/4.5 mcg 1–2 puffs PRN). Even for mild asthma (Steps 1–2), using ICS-formoterol on-demand reduces the risk of severe exacerbations by > 60% compared to SABA monotherapy.
Track 2 (Alternative Strategy): SABA reliever (Salbutamol 100–200 mcg PRN) accompanied by daily regular maintenance ICS (e.g., Beclomethasone 200–400 mcg daily). SABA monotherapy without concurrent ICS is no longer recommended by GINA at any level.
3. Chronic Obstructive Pulmonary Disease (COPD)
COPD is a progressive, non-reversible airflow limitation caused by an abnormal chronic inflammatory response of the airways and pulmonary parenchyma to noxious particles or gases.
Phenotypes and Pathophysiology
Chronic Bronchitis ('Blue Bloater'): Defined clinically by chronic productive cough for at least 3 consecutive months in each of 2 successive years , in the absence of other cardiopulmonary conditions. Characterized by goblet cell hyperplasia, mucus hypersecretion, hypoxemia, early hypercapnia, cyanosis, and secondary pulmonary hypertension progressing to cor pulmonale (right ventricular heave, elevated JVP, tender hepatomegaly, and peripheral edema).
Emphysema ('Pink Puffer'): Defined pathologically by permanent, abnormal enlargement of airspaces distal to the terminal bronchioles, accompanied by destruction of alveolar walls without gross fibrosis. Characterized by loss of elastic recoil, air trapping, barrel chest (increased anteroposterior diameter), pursed-lip breathing, decreased breath sounds, hyperresonance to percussion, and profound dyspnea with preserved normal blood gas tensions until end-stage.
Etiological Factors: Tobacco smoking is the leading global cause; however, in Kenya and across sub-Saharan Africa, indoor biomass smoke exposure (burning firewood, charcoal, and crop residues in poorly ventilated domestic kitchens) is an equally critical driver of severe COPD, especially among non-smoking rural women.
Diagnostic Confirmation: Post-bronchodilator spirometry demonstrating an F E V 1 / F V C < 0.70 FEV_1 / FVC < 0.70 FE V 1 / F V C < 0.70 confirms persistent, non-reversible airflow limitation.
Acute Exacerbation of COPD (AECOPD)
An acute worsening of respiratory symptoms beyond normal day-to-day variations that necessitates a step-up in medical therapy.
The Anthonisen Criteria for Antibiotic Initiation: Patients must exhibit at least two of the following three cardinal symptoms, one of which must be increased sputum purulence :
- Increased dyspnea
- Increased sputum volume
- Increased sputum purulence (green/yellow appearance)
Common Infective Triggers: Viruses (rhinovirus, influenza) and bacteria ( Haemophilus influenzae , Streptococcus pneumoniae , Moraxella catarrhalis , and Pseudomonas aeruginosa in advanced disease).
Principles of Controlled Oxygen Therapy
Uncontrolled, high-flow oxygen delivery in patients with acute hypercapnic COPD exacerbations can precipitate acute carbon dioxide retention, severe respiratory acidosis, coma, and death through three distinct physiological mechanisms:
Abolition of Hypoxic Pulmonary Vasoconstriction (Major Mechanism): Excess oxygen reverses compensatory vasoconstriction in poorly ventilated alveolar units, flooding poorly ventilated lung areas with perfusion and dramatically worsening ventilation-perfusion ( V / Q V/Q V / Q ) mismatch .
The Haldane Effect: Oxygenation of deoxygenated hemoglobin reduces its affinity for carbon dioxide, displacing C O 2 CO_2 C O 2 from hemoglobin into the dissolved plasma phase and elevating arterial P C O 2 PCO_2 PC O 2 .
Attenuated Peripheral Chemoreceptor Drive: Chronic carbon dioxide retainers rely partly on peripheral carotid body hypoxemia to drive ventilation; sudden correction of hypoxemia can suppress minute ventilation.
Clinical Practice Standard: Administer controlled low-flow oxygen via a 24% or 28% Venturi mask or nasal cannula at 1 to 2 L/min , strictly targeting an S p O 2 SpO_2 Sp O 2 of 88% to 92% . Obtain a repeat arterial blood gas (ABG) within 30 to 60 minutes.
Comprehensive Management of AECOPD
Inhaled Bronchodilators: Nebulized Salbutamol 2.5–5 mg combined with Ipratropium Bromide 500 mcg every 4 to 6 hours.
Systemic Corticosteroids: Oral Prednisolone 40 mg once daily for 5 days . The landmark REDUCE trial confirmed that 5 days of therapy is non-inferior to 14 days, provides equivalent clinical recovery, and minimizes steroid toxicity.
Antimicrobial Therapy: Indicated when Anthonisen criteria are fulfilled. First-line oral choices: Amoxicillin-clavulanate 625 mg PO 8-hourly, Azithromycin 500 mg PO daily, or Doxycycline 100 mg PO 12-hourly for 5 to 7 days.
Non-Invasive Positive Pressure Ventilation (NIV / BiPAP): First-line ventilatory support for acute hypercapnic respiratory failure ( p H < 7.35 pH < 7.35 p H < 7.35 and PaCO 2 > 45 mmHg \text{PaCO}_2 > 45\text{ mmHg} PaCO 2 > 45 mmHg ). NIV significantly decreases intubation rates, reduces length of stay, and reduces in-hospital mortality.